Treatment Patterns of Pediatric Patients with Atopic Dermatitis: A Claims Data Analysis.
Real-world evidence on treatment patterns of pediatric patients with atopic dermatitis (AD) is sparse. To assess current treatment patterns in pediatric AD patients. Retrospective observational analysis of commercial insurance and Medicaid administrative claims data (01/2011-12/2016) for pediatric AD patients, stratified by age and provider type. Analytic sample comprised 607,258 pediatric AD patients. Median observation period was 30.3 months; 78.6% were prescribed >1 AD medication. 86.7% were prescribed topical corticosteroids (TCS); 5.4% a calcineurin inhibitor. Systemic corticosteroids (SCS) were prescribed for 24.4% patients, of whom 51.8% had no asthma/allergic comorbidities. Of the 46.6% and 16.2% prescribed an antihistamine or montelukast, respectively, 62.0% and 41.3% had no asthma/allergic comorbidities. Systemic immunosuppressants were rarely prescribed (<0.5%). Higher potency TCS and SCS use increased with age. Treatment patterns varied by provider type; specialists were more likely to prescribe higher potency topicals and/or systemics, regardless of age. A minority of patients were treated by/referred to a specialist. Identification of AD patients relied on billing diagnoses; disease severity proxied based on treatment. Results indicate that SCS, despite known risks, and other medications with disproven efficacy in AD are frequently prescribed, suggesting a need for safer and, more effective alternatives.